Prediagnostic use of menopausal hormone therapy and long-term survival of localized epithelial ovarian cancer: The Extreme study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Prediagnostic use of menopausal hormone therapy and long-term survival of localized epithelial ovarian cancer : The Extreme study. / Duus, Alberte Hjorth; Hannibal, Charlotte Gerd; Baandrup, Louise; Zheng, Guoqiao; Galanakis, Michael; Maltesen, Thomas; Hertzum-Larsen, Rasmus; Mørch, Lina S.; Kjær, Susanne K.
In: International Journal of Cancer, Vol. 155, No. 1, 2024, p. 19-26.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Prediagnostic use of menopausal hormone therapy and long-term survival of localized epithelial ovarian cancer
T2 - The Extreme study
AU - Duus, Alberte Hjorth
AU - Hannibal, Charlotte Gerd
AU - Baandrup, Louise
AU - Zheng, Guoqiao
AU - Galanakis, Michael
AU - Maltesen, Thomas
AU - Hertzum-Larsen, Rasmus
AU - Mørch, Lina S.
AU - Kjær, Susanne K.
N1 - Publisher Copyright: © 2024 UICC.
PY - 2024
Y1 - 2024
N2 - Use of menopausal hormone therapy (MHT) prior to an epithelial ovarian cancer (EOC) diagnosis has been suggested to be associated with improved survival. In a recent nationwide cohort study, we found that prediagnostic long-term MHT use, especially estrogen therapy (ET), was associated with improved long-term survival in women with nonlocalized EOC. Our aim was to investigate the influence of prediagnostic MHT use on long-term survival among women with localized EOC in the same nationwide study. Our study cohort comprised all women aged 50 years or older with an EOC diagnosis in Denmark 2000–2014 (n = 2097) identified from the Extreme study. We collected information on usage of systemic ET and estrogen plus progestin therapy (EPT) from the Danish National Prescription Registry. By using pseudo-values, 5- and 10-year absolute and relative survival probabilities were estimated with 95% confidence intervals (CIs) while adjusting for histology, comorbidity, and income. Relative survival probabilities >1 indicate better survival. The 5-year absolute survival probabilities were 61% and 56%, respectively, among women who were nonusers and users of prediagnostic MHT, whereas these numbers were 46% and 41%, respectively, regarding 10-year survival. Use of MHT was not significantly associated with an improved 5- or 10-year survival in women with localized EOC (5-year relative survival probability = 0.95, 95% CI: 0.89–1.02; 10-year relative survival probability = 0.92, 95% CI: 0.84–1.02). Similar findings were seen for systemic ET or EPT use. Our findings do not suggest a positive benefit from prediagnostic MHT use on long-term survival of localized EOC.
AB - Use of menopausal hormone therapy (MHT) prior to an epithelial ovarian cancer (EOC) diagnosis has been suggested to be associated with improved survival. In a recent nationwide cohort study, we found that prediagnostic long-term MHT use, especially estrogen therapy (ET), was associated with improved long-term survival in women with nonlocalized EOC. Our aim was to investigate the influence of prediagnostic MHT use on long-term survival among women with localized EOC in the same nationwide study. Our study cohort comprised all women aged 50 years or older with an EOC diagnosis in Denmark 2000–2014 (n = 2097) identified from the Extreme study. We collected information on usage of systemic ET and estrogen plus progestin therapy (EPT) from the Danish National Prescription Registry. By using pseudo-values, 5- and 10-year absolute and relative survival probabilities were estimated with 95% confidence intervals (CIs) while adjusting for histology, comorbidity, and income. Relative survival probabilities >1 indicate better survival. The 5-year absolute survival probabilities were 61% and 56%, respectively, among women who were nonusers and users of prediagnostic MHT, whereas these numbers were 46% and 41%, respectively, regarding 10-year survival. Use of MHT was not significantly associated with an improved 5- or 10-year survival in women with localized EOC (5-year relative survival probability = 0.95, 95% CI: 0.89–1.02; 10-year relative survival probability = 0.92, 95% CI: 0.84–1.02). Similar findings were seen for systemic ET or EPT use. Our findings do not suggest a positive benefit from prediagnostic MHT use on long-term survival of localized EOC.
KW - long-term survival
KW - menopausal hormone therapy
KW - ovarian cancer
U2 - 10.1002/ijc.34936
DO - 10.1002/ijc.34936
M3 - Journal article
C2 - 38532545
AN - SCOPUS:85189549465
VL - 155
SP - 19
EP - 26
JO - Acta - Unio Internationalis Contra Cancrum
JF - Acta - Unio Internationalis Contra Cancrum
SN - 0898-6924
IS - 1
ER -
ID: 391620842